MaxCyte Newsroom

Deutsche Bank Upgrades MaxCyte(MXCT.US) to Buy Rating, Raises Target Price to $6.78

Moomoo NewsOct 11 09:33 ET

TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating

Moomoo NewsSep 24 07:31 ET

Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating

Moomoo NewsSep 16 09:31 ET

TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating

Moomoo NewsAug 7 00:32 ET

Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating

Moomoo NewsAug 6 09:32 ET

Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating

Moomoo NewsAug 5 09:31 ET

MaxCyte Analyst Ratings

BenzingaApr 23 11:24 ET

MaxCyte Analyst Ratings

BenzingaMar 13 08:05 ET

Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)

TipRanksJan 23 04:09 ET

Craig-Hallum Initiates Coverage On MaxCyte With Buy Rating, Announces Price Target of $7

BenzingaNov 29, 2023 11:10 ET

MaxCyte Analyst Ratings

BenzingaNov 29, 2023 11:08 ET

Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price Target

BenzingaOct 5, 2023 08:30 ET

MaxCyte Analyst Ratings

BenzingaOct 5, 2023 08:28 ET

Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price Target

BenzingaMar 28, 2023 07:26 ET

MaxCyte analyst ratings

Benzinga Analyst RatingsAug 15, 2022 07:04 ET

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

Benzinga Real-time NewsAug 15, 2022 07:04 ET